Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx

Cancer

Volumn 115, Issue 17, 2009, Pages 3909-3918

  Holsinger, F Christopher ^a   Lin, Heather Y ^a   Bassot, Vincent ^b   Laccourreye, Ollivier ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b St Francis Clinic   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Carcinoma; Complete response; Induction chemotherapy; Larynx; Pharynx

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; DYSESTHESIA; FEMALE; FOLLOW UP; GLOTTIS; HUMAN; KAPLAN MEIER METHOD; LARYNX CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL NEUROPATHY; PHARYNX CARCINOMA; PRIORITY JOURNAL; SALVAGE THERAPY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHARYNGEAL NEOPLASMS; PLATINUM COMPOUNDS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 68549130839     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24477     Document Type: Article

References (31)

1. Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1983;51:1353-1355.
2. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer. 1987;60: 1178-1183.
3. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265-272.
4. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer. 2000;83:1594-1598.
5. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21:327-333.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Fort Washington, Pa: National Comprehensive Cancer Network; 2007. Available at: http://www.nccn.org Accessed June 9, 2009.
7. Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D, Laccourreye H.Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: 5-year results. J Clin Oncol. 1996;14:2331-2336.
8. Laccourreye O, Veivers D, Hans S, Menard M, Brasnu D, Laccourreye H. Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer. 2001;92:1504-1511.
9. [No authors listed] Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685-1690.
10. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83-91.
11. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838-847.
12. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:890-899.
13. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
14. Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006;7:565-574.
15. Laccourreye H, Brasnu DF, Beutter P. Carcinoma of the laryngeal margin. Head Neck Surg. 1983;5:500-507.
16. Lefebvre JL, Buisset E, Coche-Dequeant B, et al. Epilarynx: pharynx or larynx? Head Neck. 1995;17:377-381.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons; 2002.
18. Warren S, Gates O. Multiple primary malignant tumors. Am J Cancer. 1932;16:1358-1414.
19. Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC. Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope. 2000;110:58-64.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
22. Woolson RF, Clarke WR. Statistical Methods for the Analysis of Biomedical Data. 2nd ed. New York, NY: John Wiley & Sons; 2002.
23. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997.
24. Bonfils P, Trotoux J, Bassot V. Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol. 2007;121:143-148.
25. Holsinger FC, Kies MS, Diaz EM Jr., et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009;27:1976-1982.
26. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143-1154.
27. Kaplan EL, Meier P. Non parametric estimation from incomplete estimation. J Am Stat Assoc. 1958;53:457-481.
28. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early stage nonsmall-cell lung cancer. N Engl J Med. 2006;355:570-580.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
30. Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck. 2004;26:365-372.
31. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx - induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. 2006 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2006;24(18S). Abstract 5517.